213 related articles for article (PubMed ID: 21223356)
1. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.
Liem-Moolenaar M; Rad M; Zamuner S; Cohen AF; Lemme F; Franson KL; van Gerven JM; Pich EM
Br J Clin Pharmacol; 2011 Jun; 71(6):907-16. PubMed ID: 21223356
[TBL] [Abstract][Full Text] [Related]
2. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1671-9. PubMed ID: 20142308
[TBL] [Abstract][Full Text] [Related]
3. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
[TBL] [Abstract][Full Text] [Related]
4. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
5. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.
Liem-Moolenaar M; Gray FA; de Visser SJ; Franson KL; Schoemaker RC; Schmitt JA; Cohen AF; van Gerven JM
J Psychopharmacol; 2010 Jan; 24(1):73-82. PubMed ID: 18755817
[TBL] [Abstract][Full Text] [Related]
6. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.
Liem-Moolenaar M; Zoethout RW; de Boer P; Schmidt M; de Kam ML; Cohen AF; Franson KL; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1681-7. PubMed ID: 19648218
[TBL] [Abstract][Full Text] [Related]
7. Central nervous system effects of haloperidol on THC in healthy male volunteers.
Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
[TBL] [Abstract][Full Text] [Related]
8. Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812.
Catafau AM; Bullich S; Nucci G; Burgess C; Gray F; Merlo-Pich E;
J Nucl Med; 2011 Apr; 52(4):526-34. PubMed ID: 21421726
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.
te Beek ET; Zoethout RW; Bani MS; Andorn A; Iavarone L; Klaassen ES; Fina P; van Gerven JM
J Psychopharmacol; 2012 Feb; 26(2):303-14. PubMed ID: 22219221
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
te Beek ET; Hay JL; Bullman JN; Burgess C; Nahon KJ; Klaassen ES; Gray FA; van Gerven JM
Br J Clin Pharmacol; 2013 May; 75(5):1328-39. PubMed ID: 23067311
[TBL] [Abstract][Full Text] [Related]
11. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers.
Hughes AM; Lynch P; Rhodes J; Ervine CM; Yates RA
Br J Clin Pharmacol; 1999 Sep; 48(3):323-30. PubMed ID: 10510142
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.
te Beek ET; Moerland M; de Boer P; van Nueten L; de Kam ML; Burggraaf J; Cohen AF; van Gerven JM
J Psychopharmacol; 2012 Aug; 26(8):1119-27. PubMed ID: 21890591
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.
Liem-Moolenaar M; de Boer P; Timmers M; Schoemaker RC; van Hasselt JG; Schmidt S; van Gerven JM
Br J Clin Pharmacol; 2011 Jun; 71(6):886-98. PubMed ID: 21306419
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers.
Lee DY; Lee KU; Kwon JS; Jang IJ; Cho MJ; Shin SG; Woo JI
Psychopharmacology (Berl); 1999 Jun; 144(3):272-8. PubMed ID: 10435394
[TBL] [Abstract][Full Text] [Related]
15. Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.
te Beek ET; Tatosian D; Majumdar A; Selverian D; Klaassen ES; Petty KJ; Gargano C; van Dyck K; McCrea J; Murphy G; van Gerven JM
J Clin Pharmacol; 2013 Aug; 53(8):846-56. PubMed ID: 23775877
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia.
Pouzet B; Didriksen M; Arnt J
Pharmacol Biochem Behav; 2002 Apr; 71(4):655-65. PubMed ID: 11888557
[TBL] [Abstract][Full Text] [Related]
18. Effects of tiapride on electroencephalograms and cognitive functions in the elderly.
Patat A; Alberini H; Bonhomme D; Soubrane C; Allain H; Gandon JM
Int Clin Psychopharmacol; 1999 Jul; 14(4):199-208. PubMed ID: 10468312
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
20. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.
van Steveninck AL; van Berckel BN; Schoemaker RC; Breimer DD; van Gerven JM; Cohen AF
J Psychopharmacol; 1999; 13(1):10-7. PubMed ID: 10221355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
